Acadia Pharma (ACAD) Misses Q3 EPS by 5c

November 7, 2016 4:06 PM EST

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment